CareDx, Inc
CDNA
NASDAQ8.95
CareDx, Inc
NASDAQ:CDNA
RECENT
PRICE
8.95
P/E
RATIO
-6.26
(PEG:- -)
P/E RATIO
RELATIVE
TO S&P
-0.30
DIV
YLD
0.00%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
1.03 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 03/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
- -
- -
- -
- -
- -
- -
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Fiscal year
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.77
(0.69)
(0.26)
- -
3.00
(0.48)
(0.09)
- -
4.70
0.13
(0.70)
- -
2.37
(1.16)
(0.92)
- -
2.46
(2.39)
(1.03)
- -
2.07
(2.38)
(0.62)
- -
2.15
(1.31)
(0.32)
- -
3.01
(0.52)
(0.15)
- -
4.13
(0.40)
0.50
- -
5.63
(0.58)
(0.75)
- -
6.03
(1.44)
(0.87)
- -
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
(19.97)
0.01
(20.44)
0.13
7.10
0.10
2.49
0.03
1.18
0.01
(0.26)
0.20
2.69
0.08
2.35
0.22
5.97
0.38
8.84
0.40
8.08
CAPEX per share
Book Value per share
- -
- -
- -
- -
- -
- -
7
7
6
12
16
23
36
42
46
53
53
Comm.Shares outs.(m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
60.0
3.31
- -
(5.1)
(0.26)
- -
(1.9)
(0.08)
- -
(1.3)
(0.05)
- -
(11.9)
(0.48)
- -
(54.5)
(2.25)
- -
(87.1)
(2.30)
- -
(122.0)
(4.07)
- -
(18.2)
(0.86)
- -
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/12/22 | Q4)
Total liabilities
$112 m.
Total assets
$543 m.
Long-term debt
$33 m.
Cash and equiv.
$90 m.
Goodwill $38 m.
Retained earnings $(460) m.
Common stock 53 m. shares
Market Capitalisation
$480 m. (as of 25/3/23)
- -
- -
20
(11.5)%
22
(3.9)%
27
4.6%
28
(42.4)%
41
(91.9)%
48
(42.0)%
77
(20.3)%
127
(19.3)%
192
(11.7)%
296
(10.0)%
322
(24.0)%
Revenue (m)
Operating margin
- -
- -
1
(5)
1
(4)
1
1
1
(14)
3
(39)
4
(55)
4
(47)
6
(22)
10
(19)
12
(31)
16
(77)
Depreciation (m)
Net profit (m)
- -
- -
- -
(24.7)%
- -
(16.0)%
208.6%
2.9%
- -
(48.7)%
3.9%
(97.1)%
3.0%
(114.8)%
3.0%
(61.1)%
8.3%
(17.3)%
5.2%
(9.7)%
4.4%
(10.3)%
(0.5)%
(23.8)%
Income tax rate
Net profit margin
- -
- -
- -
1
13
(147)
1
11
(151)
29
5
41
24
13
29
(14)
1
19
(16)
18
(6)
62
- -
96
37
- -
99
204
16
278
356
17
466
312
33
431
Working capital (m)
Long-term debt (m)
Equity (m)
- -
- -
- -
(68.5)%
(23.9)%
3.4%
(61.1)%
(14.1)%
2.4%
(3.0)%
2.3%
1.9%
(26.6)%
(21.8)%
(46.5)%
(105.8)%
(51.3)%
(202.6)%
(123.0)%
(61.5)%
904.3%
(38.8)%
(34.0)%
(48.7)%
(18.8)%
(15.8)%
(22.2)%
(6.3)%
(5.4)%
(6.7)%
(6.3)%
(5.7)%
(6.6)%
(16.4)%
(14.0)%
(17.8)%
ROIC
Return on capital
Return on equity
Working Capital
2020
2021
2022
Cash assets
225
439
180
Receivables
35
60
66
Inventory
10
17
19
Other
4
8
9
Current assets
273
433
388
Acc. Payable
10
13
10
Debt due
2
4
- -
Other
58
60
66
Current liab.
69
77
76
- -
- -
- -
- -
100.0%
- -
100.0%
- -
100.0%
961.2%
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
Plowback ratio
Div.&Repurch. to FCF
CareDx, Inc (US) started trading on July 4, 2014 (cik: 0001217234), operates in the Healthcare sector (Diagnostics & Research industry), has 633 full-time employees, and is led by Dr. Reginald Seeto M.D., MBBS. CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
45.00%
36.49%
Cash flow
-194.16%
-6.23%
Earnings
36.47%
-179.83%
Dividends
- -
- -
Book value
60.99%
-193.48%
Insider trading
Type
Shares
Date
Seeto Reginald
Sale
2,819
03/02/23
Seeto Reginald
Sale
8,488
02/10/23
Seeto Reginald
Sale
11,094
02/09/23
Maag Peter
Sale
3,269
02/08/23
Seeto Reginald
Sale
3,069
02/07/23
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
38
42
53
59
192
2021
67
74
76
79
296
2022
79
81
79
82
322
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
(0.13)
(0.14)
(0.06)
(0.08)
-0.40
2021
(0.01)
(0.04)
(0.23)
(0.31)
-0.58
2022
(0.37)
(0.41)
(0.32)
(0.34)
-1.44
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -